SpectraCure presents the company and the progress on their current clinical trial
SpectraCure’s CEO Masoud Khayyami will present the company and the progress on their current clinical trial today, November 13, 2017, at 14:00, at Sheraton Stockholm Hotel. The presentation will be sent live on the internet at www.aktiespararna.se/tv/live. For further information, contact:SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90 SpectraCure in short […]
The CEO of SpectraCure increases his shareholding through MK Capital
SpectraCure CEO Masoud Khayyami has, through his company MK Capital Invest, on November 8th bought 10 000 shares in SpectraCure. The shares were purchased at a rate of SEK 8.20 per share, corresponding to a transaction of SEK 82 000. The transaction was made on Aktietorget, according to the Financial Supervisory Authority (sv Finansinspektionen) transparency […]
Imaging material from clinical Phase 1 study
At the PhotonicSweden Workshop on Photonics for Life Science and Regional Innovation Strategies in Kista on October 17th, the CTO of SpectraCure, Johannes Swartling, held a lecture on the company. The company has previously announced that the last treated patient prior to treatment had a PSA value of 4.9 ng/ml and, upon revisiting after treatment, […]
Concept study for next generation product completed
SpectraCure AB has conducted a concept study for the development of the company's technology for the treatment of prostate cancer using photodynamic therapy (PDT). SpectraCures current PDT system, SpectraCure P18 with IDOSE®, has evolved over a ten-year period and is currently used in a Phase 1 clinical trial for the treatment of patients with relapse […]
More preliminary results from the clinical Phase 1 study
SpectraCure is conducting a Phase 1 clinical study for the treatment of patients with relapse in prostate cancer, using the company's photodynamic therapy (PDT) technology. As previously announced, the maximum and final dose of the drug dose product has been reached in the study. During post-treatment follow-up, the PSA value (Prostate-specific antigen) of the patient […]
Positive preliminary results from the clinical Phase 1 study are presented at a scientific conference
SpectraCure is now conducting a Phase 1 clinical study to treat patients with recurring prostate cancer using the company's photodynamic therapy (PDT) technology. As previously announced, the maximum and final dose of the photosensitising drug has been achieved in the study. Magnetic resonance images (MRI) of prostate taken one week after treatment in the patient […]
Full drug dose achieved in prostate trial
In the Phase 1 study SpectraCure is conducting for the treatment of patients with relapse of prostate cancer, the third and final level of the drug dose has now been achieved. The first full-dose patient was treated this week at the Princess Margaret Cancer Centre in Toronto, Canada. The treatment method, called photodynamic therapy (PDT), […]
EU Grant awarded through Vinnova
SpectraCure has been granted a research and development grant linked to EU's major research and innovation Framework Programme, Horizon 2020. The grant is in the Industrial leadership sub-area, and is a so-called SME instrument in Phase 1, a contribution towards small and medium-sized research companies. The grant includes SEK 500 000 in Phase 1, and […]
An additional patient has been treated in Toronto, Canada
Another patient in the SpectraCure Phase 1 study has been treated for relapse of prostate cancer at Princess Margaret Cancer Centre in Toronto, Canada. The treatment went well and the SpectraCure technology worked according to plan. There are a number of patients on the waiting list waiting for treatment. The procedure used SpectraCures IDOSE® technology for […]
Patent for dose control approved in Canada
The Canadian Patent Office has approved a patent for improved dose control for the SpectraCure technology for treatment of prostate cancer with photodynamic therapy (PDT). The patent is part of the SpectraCures patent area for dose control, covering the software IDOSE® which ensures that the correct laser light dose is delivered to the tumour to […]
